The Scorpion Toxin Analogue BmKTX-D33H As a Potential Kv1.3 Channel-Selective Immunomodulator for Autoimmune Diseases

Overview

Journal Toxins (Basel)

Publisher MDPI

Specialty Toxicology

Date 2016 Apr 23

PMID 27104568

Citations 7

Authors

Fang Ye

Youtian Hu

Weiwei Yu

Zili Xie

Jun Hu

Zhijian Cao

Wenxin Li

Yingliang Wu

Affiliations

Soon will be listed here.

Abstract

The Kv1.3 channel-acting scorpion toxins usually adopt the conserved anti-parallel β-sheet domain as the binding interface, but it remains challenging to discover some highly selective Kv1.3 channel-acting toxins. In this work, we investigated the pharmacological profile of the Kv1.3 channel-acting BmKTX-D33H, a structural analogue of the BmKTX scorpion toxin. Interestingly, BmKTX-D33H, with its conserved anti-parallel β-sheet domain as a Kv1.3 channel-interacting interface, exhibited more than 1000-fold selectivity towards the Kv1.3 channel as compared to other K⁺ channels (including Kv1.1, Kv1.2, Kv1.7, Kv11.1, KCa2.2, KCa2.3, and KCa3.1). As expected, BmKTX-D33H was found to inhibit the cytokine production and proliferation of both Jurkat cells and human T cells in vitro. It also significantly improved the delayed-type hypersensitivity (DTH) responses, an autoreactive T cell-mediated inflammation in rats. Amino acid sequence alignment and structural analysis strongly suggest that the "evolutionary" Gly11 residue of BmKTX-D33H interacts with the turret domain of Kv1 channels; it appears to be a pivotal amino acid residue with regard to the selectivity of BmKTX-D33H towards the Kv1.3 channel (in comparison with the highly homologous scorpion toxins). Together, our data indicate that BmKTX-D33H is a Kv1.3 channel-specific blocker. Finally, the remarkable selectivity of BmKTX-D33H highlights the great potential of evolutionary-guided peptide drug design in future studies.

Citing Articles

The Significant Therapeutic Effects of Chinese Scorpion: Modern Scientific Exploration of Ion Channels.

Zheng Y, Wen Q, Huang Y, Guo D Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770577 PMC: 11678150. DOI: 10.3390/ph17121735.

Antimicrobial Potential of Scorpion-Venom-Derived Peptides.

Xia Z, Xie L, Li B, Lv X, Zhang H, Cao Z Molecules. 2024; 29(21).

PMID: 39519721 PMC: 11547508. DOI: 10.3390/molecules29215080.

Application of a modified multifunctional short peptide in the treatment of periodontitis.

Zhang X, Song M, Wang H, Zhang Q, Liu Z, Deng J Sci Rep. 2024; 14(1):22855.

PMID: 39353971 PMC: 11445488. DOI: 10.1038/s41598-024-69933-z.

The toxin mimic FS48 from the salivary gland of Xenopsylla cheopis functions as a Kv1.3 channel-blocking immunomodulator of T cell activation.

Zeng Q, Lu W, Deng Z, Zhang B, Wu J, Chai J J Biol Chem. 2021; 298(1):101497.

PMID: 34919963 PMC: 8732088. DOI: 10.1016/j.jbc.2021.101497.

Anti-inflammatory activities of arthropod peptides: a systematic review.

Santos A, Cruz G, Baptista G J Venom Anim Toxins Incl Trop Dis. 2021; 27:e20200152.

PMID: 34795699 PMC: 8564866. DOI: 10.1590/1678-9199-JVATITD-2020-0152.

References

Pennington M, Chang S, Chauhan S, Huq R, Tajhya R, Chhabra S . Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK. Mar Drugs. 2015; 13(1):529-42. PMC: 4306950. DOI: 10.3390/md13010529. View

Chen Z, Hu Y, Hong J, Hu J, Yang W, Xiang F . Toxin acidic residue evolutionary function-guided design of de novo peptide drugs for the immunotherapeutic target, the Kv1.3 channel. Sci Rep. 2015; 5:9881. PMC: 4424837. DOI: 10.1038/srep09881. View

Eriksson M, Roux B . Modeling the structure of agitoxin in complex with the Shaker K+ channel: a computational approach based on experimental distance restraints extracted from thermodynamic mutant cycles. Biophys J. 2002; 83(5):2595-609. PMC: 1302345. DOI: 10.1016/S0006-3495(02)75270-3. View

Wulff H, Calabresi P, Allie R, Yun S, Pennington M, Beeton C . The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest. 2003; 111(11):1703-13. PMC: 156104. DOI: 10.1172/JCI16921. View

Wulff H, Beeton C, Chandy K . Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Discov Devel. 2003; 6(5):640-7. View

Mouhat S, Jouirou B, Mosbah A, De Waard M, Sabatier J . Diversity of folds in animal toxins acting on ion channels. Biochem J. 2003; 378(Pt 3):717-26. PMC: 1224033. DOI: 10.1042/BJ20031860. View

Chandy K, Wulff H, Beeton C, Pennington M, Gutman G, Cahalan M . K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci. 2004; 25(5):280-9. PMC: 2749963. DOI: 10.1016/j.tips.2004.03.010. View

Wu Y, Cao Z, Yi H, Jiang D, Mao X, Liu H . Simulation of the interaction between ScyTx and small conductance calcium-activated potassium channel by docking and MM-PBSA. Biophys J. 2004; 87(1):105-12. PMC: 1304333. DOI: 10.1529/biophysj.103.039156. View

Tudor J, Pallaghy P, Pennington M, Norton R . Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone. Nat Struct Biol. 1996; 3(4):317-20. DOI: 10.1038/nsb0496-317. View

10.

Kalman K, Pennington M, Lanigan M, Nguyen A, Rauer H, Mahnir V . ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. J Biol Chem. 1998; 273(49):32697-707. DOI: 10.1074/jbc.273.49.32697. View

11.

Mouhat S, Visan V, Ananthakrishnan S, Wulff H, Andreotti N, Grissmer S . K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. Biochem J. 2004; 385(Pt 1):95-104. PMC: 1134677. DOI: 10.1042/BJ20041379. View

12.

Beeton C, Pennington M, Wulff H, Singh S, Nugent D, Crossley G . Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol. 2005; 67(4):1369-81. PMC: 4275123. DOI: 10.1124/mol.104.008193. View

13.

Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hansel W . Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol. 2005; 68(5):1254-70. DOI: 10.1124/mol.105.015669. View

14.

Mouhat S, Teodorescu G, Homerick D, Visan V, Wulff H, Wu Y . Pharmacological profiling of Orthochirus scrobiculosus toxin 1 analogs with a trimmed N-terminal domain. Mol Pharmacol. 2005; 69(1):354-62. DOI: 10.1124/mol.105.017210. View

15.

Beeton C, Wulff H, Standifer N, Azam P, Mullen K, Pennington M . Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A. 2006; 103(46):17414-9. PMC: 1859943. DOI: 10.1073/pnas.0605136103. View

16.

Yi H, Cao Z, Yin S, Dai C, Wu Y, Li W . Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition. J Proteome Res. 2007; 6(2):611-20. DOI: 10.1021/pr060368g. View

17.

Dunlop J, Kamenz C, Scholtz G . Reinterpreting the morphology of the Jurassic scorpion Liassoscorpionides. Arthropod Struct Dev. 2007; 36(2):245-52. DOI: 10.1016/j.asd.2006.09.003. View

18.

Yi H, Qiu S, Cao Z, Wu Y, Li W . Molecular basis of inhibitory peptide maurotoxin recognizing Kv1.2 channel explored by ZDOCK and molecular dynamic simulations. Proteins. 2007; 70(3):844-54. DOI: 10.1002/prot.21706. View

19.

Han S, Yi H, Yin S, Chen Z, Liu H, Cao Z . Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease. J Biol Chem. 2008; 283(27):19058-65. DOI: 10.1074/jbc.M802054200. View

20.

Mouhat S, Andreotti N, Jouirou B, Sabatier J . Animal toxins acting on voltage-gated potassium channels. Curr Pharm Des. 2008; 14(24):2503-18. DOI: 10.2174/138161208785777441. View